Filing Flows › Crispr Therapeutics AG (CRSP) › Q2 2025
Crispr Therapeutics AG (CRSP) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 4, 2025
Crispr Therapeutics AG (CRSP) reported revenue of $892K for the second quarter 2025 (Q2 2025), +73% from a year earlier and +3% from the quarter before.
Crispr Therapeutics AG, Q2 2025: revenue $892K (+72% year over year), net loss $209M, operating cash flow −$114M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $892K | +3% | +73% |
| Operating profit | −$229M | — | — |
| Net earnings | −$209M | — | — |
| Operating cash flow | −$114M | — | — |
What changed
Revenue was $892K in Q2 2025, up 73% year over year and up 3% from the previous quarter.
Operating costs exceeded revenue by $229.3M, an operating margin of -25709.0%. Total costs grew 52% against revenue growth of 73%. The fastest-growing cost line was Other operating costs (+171%). The quarter ended with a net loss of $208.5M, wider than the previous quarter's $136.0M loss.
Operating cash flow was −$113.9M. Non-cash charges added back $4.6M of depreciation and amortization and $17.6M of share-based compensation. Working capital and other items added $72.4M. Capital expenditures of $117K exceeded it, leaving free cash flow of −$114.0M.
Questions
What was Crispr Therapeutics AG's revenue in the second quarter 2025?
Crispr Therapeutics AG (CRSP) reported revenue of $892K for the second quarter 2025 (Q2 2025), +73% from a year earlier and +3% from the quarter before.